立体定向体部放疗后前列腺内免疫环境以髓系细胞为主
研究比较了高危非转移性前列腺癌患者接受或不接受新辅助立体定向体部放疗(SBRT)后前列腺肿瘤内免疫浸润的差异。SBRT组(n=9)在手术前2周完成3次8 Gy放疗,对照组(n=7)直接手术。流式细胞术分析显示SBRT后髓系CD45+细胞比例升高、淋巴细胞比例降低,但差异均未达统计学显著性(P=0.11)。结论认为SBRT促使前列腺肿瘤免疫浸润从淋巴系向髓系偏移。
要点
- SBRT后前列腺肿瘤免疫浸润以髓系细胞为主,淋巴系biased消失。
- 髓系CD45+细胞比例SBRT组48.4% vs 对照组25.4%,校正P=0.11。
- CD3+ T细胞比例SBRT组35.2% vs 对照组60.9%,P=0.12。
核心结论
- SBRT drives a significant lymphoid to myeloid shift in the prostate-tumor immune infiltrate.
- 该免疫偏移可能影响SBRT与免疫治疗联合的策略设计。
研究设计与样本
- 9例接受新辅助SBRT(3次8 Gy,5天内完成,手术前2周结束),7例直接行根治性前列腺切除术。
- 新鲜切除标本制备单细胞悬液,用两个14抗体面板进行多色流式细胞术免疫表型分析。
主要发现
- SBRT后2周前列腺肿瘤免疫浸润以髓系细胞为主,未放疗者更偏淋巴系。
- 髓系CD45+细胞:SBRT组48.4 ± 19.7% vs 对照组25.4 ± 7.0%,校正P=0.11。
- CD45+淋巴细胞:SBRT组51.6 ± 19.7% vs 对照组74.5 ± 7.0%,P=0.11。
- CD3+ T细胞:SBRT组35.2 ± 23.8% vs 对照组60.9 ± 9.7%,P=0.12。
临床怎么用
- 考虑SBRT联合免疫检查点阻断时,需关注放疗后髓系细胞主导的免疫微环境可能影响疗效。
- 治疗窗口(手术前2周)内观察到的免疫偏移可为联合时序设计提供参考。
局限性
- 单中心、探索性研究,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hundreds of ongoing clinical trials combine radiation therapy, mostly delivered as stereotactic body radiotherapy (SBRT), with immune checkpoint blockade. However, our understanding of the effect of radiotherapy on the intratumoral immune balance is inadequate, hindering the optimal design of trials that combine radiation therapy with immunotherapy. Our objective was to characterize the intratumoral immune balance of the malignant prostate after SBRT in patients. METHODS: Sixteen patients with high-risk, non-metastatic prostate cancer at comparable Gleason Grade disease underwent radical prostatectomy with (n = 9) or without (n = 7) neoadjuvant SBRT delivered in three fractions of 8 Gy over 5 days completed 2 weeks before surgery. Freshly resected prostate specimens were processed to obtain single-cell suspensions, and immune-phenotyped for major lymphoid and myeloid cell subsets by staining with two separate 14-antibody panels and multicolor flow cytometry analysis. RESULTS: Malignant prostates 2 weeks after SBRT had an immune infiltrate dominated by myeloid cells, whereas malignant prostates without preoperative treatment were more lymphoid-biased (myeloid CD45+ cells 48.4 ± 19.7% vs. 25.4 ± 7.0%; adjusted p-value = 0.11; and CD45+ lymphocytes 51.6 ± 19.7% vs. 74.5 ± 7.0%; p = 0.11; CD3+ T cells 35.2 ± 23.8% vs. 60.9 ± 9.7%; p = 0.12; mean ± SD). CONCLUSION: SBRT drives a significant lymphoid to myeloid shift in the prostate-tumor immune infiltrate. This may be of interest when combining SBRT with immunotherapies, particularly in prostate cancer.
引用
- Nickols NG, Ganapathy E, Nguyen C, et al. The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. Prostate Cancer Prostatic Dis. 2020. PMID: 32647353. doi:10.1038/s41391-020-0249-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。